Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 6/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.61 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961790 | 0.92 | KCNA3 (0.63) | ADRA1DADRA1AADRA1BKCNA3OPRM1 | |
| SCHEMBL6197539 | 0.88 | KCNA3 (0.77) | ADRA1AKCNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL6643987 | 0.85 | OPRM1 (0.53) | ADRA1DADRA1AADRA1BKCNA3OPRM1 | |
| SCHEMBL7965695 | 0.84 | ADRA1D (0.61) | ADRA1DADRA1AADRA1BKCNA3OPRM1 | |
| SCHEMBL14534189 | 0.81 | OPRM1 (0.71) | ADRA1DADRA1AADRA1BKCNA3OPRM1 | |
| SCHEMBL7965697 | 0.80 | KCNA3 (0.57) | ADRA1DADRA1AADRA1BKCNA3OPRM1 | |
| SCHEMBL6746046 | 0.80 | KDM4E (0.60) | ADRA1DADRA1AADRA1BKCNA3OPRM1 | |
| Hydrochloric Acid SCHEMBL7238403 | 0.79 | GAA (0.57) | KCNA3OPRM1OPRD1OPRK1GAA | |
| SCHEMBL973774 | 0.79 | HSD11B1 (0.56) | ADRA1DADRA1AADRA1BKCNA3OPRM1 | |
| SCHEMBL6966092 | 0.77 | DRD3 (0.57) | ADRA1DADRA1AADRA1BKCNA3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021185-A4 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6727257-B1 | HYPOTENSIVE AGENTS FOR INTRAOCULAR PRESSURE; ANTICHOLESTEROL AGENTS; RELAXING URINARY TRACT TISSUE; BENIGN PROSTATIC HYPERPLASIA, IMPOTENCY, AND CARDIOVASCULAR DISORDERS; ANTIARRHYTHMIA AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20030212062-A1 | Morpholinone and morpholine derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-11-13 | — | — | US | disclosed |
| US-6620815-B1 | Selective antagonists for human alpha 1A receptors; benign prostatic hyperplasia, impotency, cardiac arrhythmia treatment; anticholesterol agents; intraocular pressure reduction | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-16 | — | — | US | disclosed |
| US-6608086-B2 | Selective adrenergic receptor alpha 1C antagonists without significant calcium channel activity; treating benign prostatic hyperplasia, intraocular pressure and inhibiting cholesterol synthesis | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-19 | — | — | US | disclosed |
| EP-0988295-A4 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6531471-B2 | Antagonists for human alpha 1a receptors; lowering intraocular pressure; inhibiting cholesterol synthesis; relaxing lower urinary tract tissue; treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, etc. | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-03-11 | — | — | US | disclosed |
| US-20020193599-A1 | Dihydropyridines and new uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-19 | — | — | US | disclosed |
| US-20020068737-A1 | Morpholinone and morpholine derivatives and uses thereof | SYNAPTIC PHARAMCEUTICAL CORPORATION | 2002-06-06 | — | — | US | disclosed |
| US-6362182-B1 | HYPOTENSIVE AGENTS; ANTICHOLESTEROL AGENTS; BENIGN PROSTATIC HYPERTROPIC | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-03-26 | — | — | US | disclosed |
| EP-0988295-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-29 | — | — | EP | disclosed |
| US-5942517-A | ANTAGONIST OF ALPHA(1C) RECEPTORS; TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1998057940-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998051311-A2 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-11-19 | — | — | WO | disclosed |
| EP-0790826-A4 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 1998-11-11 | — | — | EP | disclosed |
| US-5767131-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, INHIBITION OF CHOLESTEROL SYNTHESIS, LOWERING OF INTRAOCULAR PRESSURE; ALPHA-ADRENERGIC RECEPTOR DISEASES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1997042956-A1 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0790826-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996014846-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| WO-1994022829-A2 | DIHYDROPYRIDINES AND NEW USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193599-A1 | Dihydropyridines and new uses thereof | BPHL, BCKDK, DHCR7 | ADRA1D 77/4885ADRA1A 73/4885ADRA1B 43/4885 |
| US-20020068737-A1 | Morpholinone and morpholine derivatives and uses thereof | ADRA1D, ADRA1A, ADRB1 | ADRA1D 1/4885ADRA1A 2/4885ADRA1B 7/4885 |
| US-20030212062-A1 | Morpholinone and morpholine derivatives and uses thereof | ADRA1D, ADRA1A, ADRB1 | ADRA1D 1/4885ADRA1A 2/4885ADRA1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.